ADVFN - Advanced Financial Network.
HOME» NASDAQ » I » ISIS Stock Price » ISIS Stock News

Isis Pharmaceuticals Share News

 Isis Pharmaceuticals (mm) Stock Price
ISIS Stock Price
 Isis Pharmaceuticals (mm) Stock Chart
ISIS Stock Chart
 Isis Pharmaceuticals (mm) Stock News
ISIS Stock News
 Isis Pharmaceuticals (mm) Company Information
ISIS Company Information
 Isis Pharmaceuticals (mm) Stock Trades
ISIS Stock Trades

Sanofi: Strategic Partnership With Regulus Therapeutics

PARIS -(Dow Jones)- French pharmaceutical group Sanofi Aventis (SNY) and U.S.-basec company Regulus Inc. Tuesday said they entered into a global strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance will initially focus on the therapeutic area of fibrosis. MAIN FACTS: - MicroRNAs (micro-RiboNucleic Acid) are a new class of small non-coding RNAs that regulate gene expression by interfering with translation or stability of target messenger RNA transcripts. Endogenous microRNAs regulate the expression of over one-third of all human genes. The association of microRNA dysfunction with disease phenotypes has given rise to an entirely new class of pharmaceutically relevant targets. - Sanofi-Aventis and Regulus will collaborate on microRNA drug discovery and preclinical development for up to four microRNA targets, including the lead fibrosis program targeting microRNA-21. Sanofi-Aventis also received an option, which if exercised, provides access to the technology to develop and commercialize other micro-RNA based therapeutics, beyond the first four targets. - Regulus will receive a $25 million upfront fee and a future $10 million equity investment subject to mutual agreement on company valuation. The alliance could be valued at over $750 million when taking into account upfront payments, equity investment, research funding, and potential near-term preclinical, clinical and commercial milestone payments for multiple products. - Regulus was formed in 2007 and is jointly owned by Alnylam Pharmaceuticals and Isis Pharmaceuticals. - By Paris Bureau, Dow Jones Newswires; +331-4017-1740; paris@priority.emea.dowjones.com

Stock News for Isis Pharmaceuticals (ISIS)
DateTimeHeadline
08/04/201509:16:19Current Report Filing (8-k)
08/04/201509:00:00Isis Reports Financial Results And Highlights For Second Quarter...
08/03/201517:00:00Isis Reports Positive Data from KYNAMRO® (mipomersen sodium...
08/03/201506:30:11Current Report Filing (8-k)
08/03/201502:00:00AstraZeneca and Isis Pharmaceuticals to Discover and Develop...
07/30/201509:10:00Market Updates on Drug Manufacturers - Other Equities -- Isis...
07/29/201517:06:00Positive Clinical Data From Volanesorsen Published in the New...
07/28/201507:00:00Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial...
07/27/201507:00:00ISIS Pharmaceuticals Reports Data from ISIS-TTR Rx in patients...
07/22/201519:17:00Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx...
07/21/201507:00:00Isis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx...
07/14/201507:00:00Isis Pharmaceuticals Earns $2.15M For Advancing ISIS-SMN Rx in...
07/08/201517:56:17Statement of Changes in Beneficial Ownership (4)
07/08/201517:55:36Statement of Changes in Beneficial Ownership (4)
07/08/201511:55:323 Stocks to Buy in a Market Crash
07/06/201507:00:00Akcea Therapeutics Receives Orphan Drug Designation from the...
07/02/201518:07:52Statement of Changes in Beneficial Ownership (4)
07/02/201518:06:59Statement of Changes in Beneficial Ownership (4)
07/02/201518:06:32Statement of Changes in Beneficial Ownership (4)
07/02/201518:05:40Statement of Changes in Beneficial Ownership (4)

Isis Pharmaceuticals and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad